Joint Clinical Trials Office

What does the study involve?

If you are interested, a research coordinator will give you detailed information about the study. You will be asked to sign an informed consent form. There will be approximately 8 study visits spread out over 1 year. Study procedures include tests of thinking abilities, blood tests, two MRI scans and one PET scan to measure amyloid in the brain. There will be injection of study drug (Leuprolide or placebo) 4 times over 1 year. 

LUCINDA

Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer

The purpose of this study is to see if early treatment of your metastatic colorectal cancer and circulating tumor DNA (ctDNA) positivity or negativity, with FOLFIRI, Nivolumab or Encorafenib /Binimetinib/ Cetuximab, helps to prevent stage IV disease. 

Phase I/II Dose-Escalation Study of Fractionated and Multiple Dose 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

The purpose of the initial (phase I) portion of this study is to find a dose level and administration schedule of the study drug, 225Ac-J591 that can be given without severe side effects. Following selection of the proper dose for each treatment regimen, the purpose of the phase II portion of the study is to test if the regimen of 225Ac-J591 leads to treatment response.
   

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

This study is being done to answer the following question: Can we prolong life for patients with advanced kidney cancer, by adding a drug called cabozantinib to another treatment after receiving the standard treatment? 

Experiences, Perceptions, and Needs of Critical Care Fellows During the COVID-19 Pandemic

The purpose of this study is to identify and analyze the experiences of critical care fellows during the COVID-19 pandemic. The goal is to document the challenges and perceptions of the fellows who were training and working in New York City hospitals during the crisis, and to improve clinician support and patient care.

National Marrow Donor Program (NMDP) and Center for International Blood and Marrow Transplant Research (CIBMTR) – Research Database for Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

The CIBMTR does research with medical data from patients who have had a transplant or other cellular therapy and donors who donate bone marrow or peripheral blood stem cells (PBSCs). The goal of this research is to find ways to make bone marrow and PBSC transplants and other cellular therapies work better.

Protocol for A Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

The purpose of storing a blood sample from donors and their recipients in the NMDP/CIBMTR Research Sample Repository is to provide cells and plasma (the liquid portion of blood) for the NMDP/CIBMTR Research Sample Repository. By studying the cells and plasma of donors and recipients, researchers may learn more about improving the tissue matching between unrelated donors and their recipients. Increasing knowledge about tissue matching could result in the improved long-term survival of bone marrow and stem cell transplant recipients.

A Multi-center Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adults Patients with Hematologic Malignancies and Other Indications

Cord blood (CB) is blood that is taken from the umbilical cord and placenta of healthy newborn babies after childbirth. The cord blood collected from a newborn baby is called a cord blood unit. Cord blood units are stored frozen (cryopreserved) in public cord blood banks. Approximately 10,000 cord blood transplants have been performed in children and adults for blood cancers and other blood diseases in the world.

Indications for Use of CD34 Selection Column (CliniMACS-Miltenyi Biotec)

The purpose of this study is to provide cell therapy to you, which will involve the use of CliniMACS CD34 Selection Device. Your family member or an unrelated (donor) will have to undergo a stem cell collection. The donation process that your family member or the unrelated donor will undergo is standard practice.